Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 504784, 5 pages
http://dx.doi.org/10.1155/2015/504784
Research Article

High Variability of Fabry Disease Manifestations in an Extended Italian Family

1Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, 90146 Palermo, Italy
2Internal Medicine, Nephrology and Dialysis Unit, Department of Medical and Pediatric Sciences, University of Catania, 95100 Catania, Italy
3Institute of Neurological Sciences (ISN), National Research Council, 95126 Catania, Italy
4Complex Operative Unit of Neurology, S. Antonio Abate Hospital, 91016 Trapani, Italy
5Department of Neurology, “R. Guzzardi” Hospital, ASP Ragusa, Vittoria, 97019 Ragusa, Italy
6Department of Biopathology and Medical and Forensic Biotechnology, Section of Biology and Genetics, University of Palermo, 90133 Palermo, Italy
7Cardio-Thorax-Vascular and Transplant Department, University of Catania, 95125 Catania, Italy

Received 11 December 2014; Revised 11 March 2015; Accepted 24 March 2015

Academic Editor: Janusz Blasiak

Copyright © 2015 Giuseppe Cammarata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. O. Brady, A. E. Gal, R. M. Bradley, E. Martensson, A. L. Warshaw, and L. Laster, “Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency,” The New England Journal of Medicine, vol. 276, no. 21, pp. 1163–1167, 1967. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Desnick, Y. A. Ioannou, and C. M. Eng, “Alpha-galactosidase A deficiency: fabry disease,” in The Metabolic and Molecular Basis of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., pp. 3733–3774, McGraw-Hill, New York, NY, USA, 8th edition, 2001. View at Google Scholar
  3. R. Kornreich, D. F. Bishop, and R. J. Desnick, “The gene encoding alpha-galactosidase A and gene rearrangements causing Fabry disease,” Transactions of the Association of American Physicians, vol. 102, pp. 30–43, 1989. View at Google Scholar · View at Scopus
  4. D. A. Zeevi, E. Hakam-Spector, Y. Herskovitz, R. Beeri, D. Elstein, and G. Altarescu, “An intronic haplotype in α-galactosidase A is associated with reduced mRNA expression in males with cryptogenic stroke,” Gene, vol. 549, no. 2, pp. 275–279, 2014. View at Publisher · View at Google Scholar
  5. A. Tuttolomondo, G. Duro, R. Pecoraro et al., “A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene,” Clinical Biochemistry, vol. 48, no. 1-2, pp. 55–62, 2015. View at Publisher · View at Google Scholar
  6. M. F. Lyon, “Gene action in the X-chromosome of the mouse (Mus musculus L.),” Nature, vol. 190, no. 4773, pp. 372–373, 1961. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Nakao, C. Kodama, T. Takenaka et al., “Fabry disease: detection of undiagnosed hemodialysis patients and identification of a ‘renal variant’ phenotype,” Kidney International, vol. 64, no. 3, pp. 801–807, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. C. M. Eng, M. Banikazemi, R. E. Gordon et al., “A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies,” The American Journal of Human Genetics, vol. 68, no. 3, pp. 711–722, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Pisani, B. Visciano, G. D. Roux et al., “Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature,” Molecular Genetics and Metabolism, vol. 107, no. 3, pp. 267–275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. J. Desnick and E. H. Schuchman, “Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges,” Annual Review of Genomics and Human Genetics, vol. 13, pp. 307–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Rombach, B. E. Smid, G. E. Linthorst, M. G. W. Dijkgraaf, and C. E. M. Hollak, “Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis,” Journal of Inherited Metabolic Disease, vol. 37, no. 3, pp. 341–352, 2014. View at Publisher · View at Google Scholar
  12. O. Lidove, P. Kaminsky, E. Hachulla et al., “Fabry disease ‘The New great Imposter’: results of the French observatoire in internal medicine departments (FIMeD),” Clinical Genetics, vol. 81, no. 6, pp. 571–577, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Hoffmann and E. Mayatepek, “Fabry disease—often seen, rarely diagnosed,” Deutsches Arzteblatt, vol. 106, no. 26, pp. 440–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Spada, S. Pagliardini, M. Yasuda et al., “High incidence of later-onset Fabry disease revealed by newborn screening,” The American Journal of Human Genetics, vol. 79, no. 1, pp. 31–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W. L. Hwu, Y. H. Chien, N. C. Lee et al., “Newborn screening for fabry disease in taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G> (IVS4+919G>A),” Human Mutation, vol. 30, no. 10, pp. 1397–1405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Callegaro and D. R. Kaimen-Maciel, “Fabry's disease as a differential diagnosis of MS,” International MS Journal, vol. 13, no. 1, pp. 27–30, 2006. View at Google Scholar · View at Scopus
  17. N. A. Chamoles, M. Blanco, and D. Gaggioli, “Fabry disease: enzymatic diagnosis in dried blood spots on filter paper,” Clinica Chimica Acta, vol. 308, no. 1-2, pp. 195–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. C. L. Marchesoni, N. Roa, A. M. Pardal et al., “Misdiagnosis in Fabry disease,” Journal of Pediatrics, vol. 156, no. 5, pp. 828–831, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. E. Gutiérrez-Amavizca, R. Orozco-Castellanos, J. R. Padilla-Gutiérrez, Y. Valle, and L. Figuera, “Pedigree analysis of Mexican families with Fabry disease as a powerful tool for identification of heterozygous females,” Genetics and Molecular Research, vol. 13, no. 3, pp. 6752–6758, 2014. View at Publisher · View at Google Scholar
  20. C. Riera, S. Lois, C. Domínguez et al., “Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations,” Proteins, vol. 83, no. 1, pp. 91–104, 2015. View at Publisher · View at Google Scholar
  21. T. Tsukimura, Y. Chiba, K. Ohno, S. Saito, Y. Tajima, and H. Sakuraba, “Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars,” Molecular Genetics and Metabolism, vol. 103, no. 1, pp. 26–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Lukas, J. Torras, I. Navarro et al., “Broad spectrum of Fabry disease manifestation in an extended Spanish family with a new deletion in the GLA gene,” Clinical Kidney Journal, vol. 5, no. 5, pp. 395–400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Rigoldi, D. Concolino, A. Morrone et al., “Intrafamilial phenotypic variability in four families with Anderson-Fabry disease,” Clinical Genetics, vol. 86, no. 3, pp. 258–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Jakóbkiewicz-Banecka, M. Gabig-Cimińska, Z. Banecka-Majkutewicz, B. Banecki, A. Węgrzyn, and G. Węgrzyn, “Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases,” Metabolic Brain Disease, vol. 29, no. 1, pp. 1–8, 2014. View at Publisher · View at Google Scholar